Key Highlights
- Third-quarter Revenue was USD 102,884, down 66.1%.
- Operating expenses fell 36.5% to USD 1.5 million.
- Net loss was USD 31.6 million on a USD 30.4 million commitment fee.
- The nine-month net loss was USD 38.7 million.
One charge explains the headline loss at Onconetix (NASDAQ:ONCO). The company attributes the third-quarter net loss of USD 31,627,931, against USD 8,783,702, mainly to USD 30.4 million of commitment fee expense from an Equity line of Credit purchase agreement signed in July 2026. The prior-year quarter held about USD 5.4 million of loss on extinguishment of notes and USD 2.5 million of loss on issuance of preferred stock and warrants.
Revenue was USD 102,884, down 66.1% from USD 303,651. Gross Profit was USD 78,166 versus USD 268,894, and gross Margin fell to 76.0% from 88.6%, because last year's revenue was mostly license revenue with minimal associated cost. Royalty revenues were de minimis.
Total operating expenses fell 36.5% to USD 1,484,439 from USD 2,338,136, and the loss from operations narrowed 32.0% to USD 1,406,273. Selling, general and administrative expenses dropped about USD 0.9 million on lower professional fees and legal costs. No income tax expense was recorded in either period. The loss per share was USD 76.01 versus USD 3,124.76, adjusted for the company's share changes. No estimates existed for the quarter.
Nine Months
Revenue for nine months was USD 141,461 versus USD 511,775, down 72.4%, and gross profit was USD 80,814 versus USD 385,229. Operating expenses were USD 14,443,678 versus USD 16,960,718, and the loss from operations narrowed 13.3% to USD 14,362,864. The net loss was USD 38,710,109 versus USD 19,702,029, or USD 178.02 per share.
Balance Sheet
Cash was USD 2,741,657 versus USD 5,220,654 at year-end, and the company held a USD 2,500,000 note receivable. Total Assets were USD 15,545,227 versus USD 24,926,638, with Goodwill of USD 9,328,449 versus USD 18,549,005. Accounts Receivable were USD 103,421 versus USD 296,866, inventories were USD 192,644 versus USD 149,961 and total current assets were USD 5,937,415 versus USD 6,066,774.
Total liabilities were USD 4,035,219 versus USD 9,160,287, and derivative liabilities were USD 2,040,212 versus USD 6,985,347. Accounts Payable were USD 1,332,555 versus USD 1,757,695, accrued expenses were USD 531,406 versus USD 341,881 and total current liabilities were USD 4,029,405 versus USD 9,135,925. Series F redeemable preferred stock of 37,562 shares was carried at USD 28,798,350. The accumulated Deficit was USD 169,924,667, additional paid-in Capital was USD 154,153,018, and 550,328 common shares were outstanding versus 3,117 at year-end.
The Business
Onconetix is a commercial-stage biotechnology company focused on oncology. In December 2023 it acquired Proteomedix AG, a Swiss company that owns the Proclarix diagnostic product. Research and Development expense in the quarter reflected a new clinical study agreement with LabCorp. Revenue from Proclarix, the effect of the equity line on share count and per-share results, and Operating Expense levels are the points to follow.






Please wait processing your request...